Abstract:Floxuridine (FUdR, 5-fluoro-2-deoxyuridine) was widely used in patients with tumor. But the poor activity and severe side effects have been observed in the clinic, which resulted from increased degradation cleavage of FUdR to 5-FU by thymidine phosphorylase and reduced transporter-mediated entry into cells. In this study, we have synthesized a series of l-aspartic acid β-esters and l-glutamic acid γ-esters of FUdR to improve the metabolic stability of FUdR and target FUdR to cancer cells via amino acid transporter ATB0,+ which was exclusively up-regulated in some cancerous tissue. The uptake mechanism, stability, in vitro/in vivo antiproliferation action, pharmacokinetics, and tissue distribution were studied. The combined results showed the unusual 5′-β-l-Asp-FUdR possessed a better tumor inhibition rate and a better metabolic stability than FUdR through a ATB0,+-mediated prodrug approach. The present study provided the first proof-of-concept of exploiting ATB0,+ for tumor-selective delivery of nucleoside analogues in the form of prodrug.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00149?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00149</a>.1H NMR (400 MHz, DMSO-d6), 13C NMR (100 MHz, DMSO-d6), and HPLC of 5′-α-l-Val-FUdR, 3′-α-l-Val-FUdR, 3′,5′-di-α-l-Val-FUdR, 5′-β-l-Asp-FUdR, 3′-β-l-Asp-FUdR, 3′,5′-di-β-l-Asp-FUdR, 5′-γ-l-Glu-FUdR, 3′-γ-l-Glu-FUdR, and 3′,5′-di-γ-l-Glu-FUdR (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00149/suppl_file/jm0c00149_si_001.pdf">PDF</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00149/suppl_file/jm0c00149_si_002.csv">CSV</a>)Coordinates of homology models for ATB0,+ (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00149/suppl_file/jm0c00149_si_003.pdb">PDB</a>)This article has not yet been cited by other publications.

Novel ProTide Prodrugs of 5-Fluoro-2′-deoxyuridine for the Treatment of Liver Cancer

Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2 '-Deoxyuridine for the Treatment of Hepatocellular Carcinoma

5-Fluorouracil Nanoparticles Inhibit Hepatocellular Carcinoma Via Activation of the P53 Pathway in the Orthotopic Transplant Mouse Model

Design, Synthesis, and Evaluation of Doxifluridine Derivatives as Nitroreductase-Responsive Anticancer Prodrugs

Optimized 5-Fluorouridine Prodrug for Co-Loading with Doxorubicin in Clinically Relevant Liposomes

Bifunctional and Unusual Amino Acid β- or γ-Ester Prodrugs of Nucleoside Analogues for Improved Affinity to ATB 0,+ and Enhanced Metabolic Stability: An Application to Floxuridine

Synthesis of Novel Spin-Labeled Derivatives of 5-FU As Potential Antineoplastic Agents

Liver-targeting Resibufogenin-loaded poly(lactic-co-glycolic acid)-D-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles for liver cancer therapy

Enhanced Liver Targeting by Synthesis of N 1 -Stearyl-5-fu and Incorporation into Solid Lipid Nanoparticles

Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy

Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy

Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents

[Preparation of Floxuridine Loaded Polycation and Its Antitumor Activity].

N(3)-o-toluyl-fluorouracil Inhibits Human Hepatocellular Carcinoma Cell Growth Via Sustained Release of 5-FU.

Synthesis and Characterization of New Liver Targeting 5-Fluorouracil-cholic Acid Conjugates

Synthesis of Novel Nucleoside Analogue Phosphorothioamidate Prodrugs and in Vitro Anticancer Evaluation Against RKO Human Colon Carcinoma Cells

A Novel Brain Targeted 5-Fu Derivative with Potential Antitumor Efficiency and Decreased Acute Toxicity: Synthesis, in Vitro and in Vivo Evaluation.

An NAD(P)H:Quinone Oxidoreductase 1 Responsive and Self-Immolative Prodrug of 5-Fluorouracil for Safe and Effective Cancer Therapy

The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

Design and Synthesis of Parthenolide and 5-Fluorouracil Conjugates As Potential Anticancer Agents Against Drug Resistant Hepatocellular Carcinoma.

Synthesis of novel oxazol-5-one derivatives containing chiral trifluoromethyl and isoxazole moieties as potent antitumor agents and the mechanism investigation